Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-01-29
DOI
10.1002/cpt.1377
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study
- (2018) MaryAnn Zhang et al. CIRCULATION
- Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions
- (2018) Chuang-Wei Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- (2018) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions
- (2017) Ching-Hua Ke et al. JOURNAL OF RHEUMATOLOGY
- Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis
- (2017) Tony Zhang et al. RHEUMATOLOGY
- Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
- (2017) Catrin O. Plumpton et al. RHEUMATOLOGY
- Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions
- (2016) Chuang-Wei Wang et al. Current Opinion in Allergy and Clinical Immunology
- Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
- (2016) Thomas Bardin et al. JOINT BONE SPINE
- Severe cutaneous adverse drug reactions
- (2016) Wen-Hung Chung et al. JOURNAL OF DERMATOLOGY
- Impact of the HLA-B * 58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions
- (2016) Chau Yee Ng et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study
- (2015) Seoyoung C. Kim et al. AMERICAN JOURNAL OF MEDICINE
- Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions
- (2015) Wen-Hung Chung et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Allopurinol Use and Risk of Fatal Hypersensitivity Reactions
- (2015) Chien-Yi Yang et al. JAMA Internal Medicine
- Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin
- (2014) Wen-Hung Chung et al. ANNALS OF THE RHEUMATIC DISEASES
- An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout
- (2014) George Nuki CURRENT OPINION IN RHEUMATOLOGY
- Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population
- (2014) Surasak Saokaew et al. PLoS One
- An Allopurinol-Controlled, Randomized, Double-Dummy, Double-Blind, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan
- (2012) Naoyuki Kamatani et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Febuxostat Hypersensitivity
- (2012) A. M. ABELES JOURNAL OF RHEUMATOLOGY
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
- (2012) Dinesh Khanna et al. ARTHRITIS CARE & RESEARCH
- The DRESS Syndrome: A Literature Review
- (2011) Patrice Cacoub et al. AMERICAN JOURNAL OF MEDICINE
- Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
- (2011) Ratchadaporn Somkrua et al. BMC Medical Genetics
- Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib
- (2011) M. Back et al. EUROPEAN HEART JOURNAL
- Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans
- (2011) Hye-Ryun Kang et al. Pharmacogenetics and Genomics
- ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis
- (2010) B Sassolas et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout
- (2010) E. Krishnan RHEUMATOLOGY
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
- (2010) Michael A Becker et al. ARTHRITIS RESEARCH & THERAPY
- Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population
- (2009) Wichittra Tassaneeyakul et al. Pharmacogenetics and Genomics
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial
- (2008) H. RALPH Schumacher et al. ARTHRITIS AND RHEUMATISM
- A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
- (2008) Christine Lonjou et al. Pharmacogenetics and Genomics
- HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis
- (2008) Nahoko Kaniwa et al. PHARMACOGENOMICS
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
- (2007) Sima Halevy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started